Meet Benchling, the latest unicorn seeking to revolutionize the way scientists do work with the help of the cloud

Nicole DeFeudis

Editor

There’s another unicorn in biotech land, as Benchling and its leading R&D cloud platform pull in a $200 million Series E to help scientists accelerate …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Meet Benchling, the latest unicorn seeking to revolutionize the way scientists do work with the help of the cloud

Nicole DeFeudis

Editor

Sign up to read this article for free.

Ideaya inks ADC deal with $75M upfront; Amylyx, Gubra to develop long-acting GLP-1

Despite mixed data in Alzheimer's agitation, Axsome will still seek FDA approval

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

FDA approves subcutaneous version of Bristol Myers' Opdivo

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties

WuXi AppTec will sell cell and gene therapy business to private equity firm

Meet Bench­ling, the lat­est uni­corn seek­ing to rev­o­lu­tion­ize the way sci­en­tists do work with the help of the cloud

Nicole DeFeudis

Editor

Sign up to read this article for free.

more like this

Ideaya inks ADC deal with $75M up­front; Amy­lyx, Gubra to de­vel­op long-act­ing GLP-1

De­spite mixed da­ta in Alzheimer's ag­i­ta­tion, Ax­some will still seek FDA ap­proval

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

Meet Benchling, the latest unicorn seeking to revolutionize the way scientists do work with the help of the cloud

Ideaya inks ADC deal with $75M upfront; Amylyx, Gubra to develop long-acting GLP-1

Despite mixed data in Alzheimer's agitation, Axsome will still seek FDA approval

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

FDA approves subcutaneous version of Bristol Myers' Opdivo

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties

WuXi AppTec will sell cell and gene therapy business to private equity firm